Search clinical trials for: Monovalent influenza A/H7N9 virus vaccine

Total 295 results

National Institute of Allergy and Infectious Diseases...

Completed

A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Boost in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Influenza | Avian Influenza | H1N1 Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Avian Influenza | Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

2013/2017 H7N9 Prime-Boost Interval

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Adults

Influenza

United States
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Avian Influenza

United States
Hualan Biological Bacterin Co. Ltd.

Completed

Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population

Influenza A
National Institute of Allergy and Infectious Diseases...
University of Rochester

Completed

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

Influenza A Virus, H7N9 Subtype

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Influenza A Virus, H7N9 Subtype

United States
GlaxoSmithKline

Completed

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

Influenza

Canada
University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Influenza

United States
GlaxoSmithKline

Completed

A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age

Influenza

Taiwan, Thailand
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
National Taiwan University Hospital

Unknown

Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients

Serology Analysis | Novel H1N1 Influenza Vaccination | Pediatric Haemato-oncology Patients

Taiwan
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

Influenza

Japan
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 (Clade 2) Vaccination of Adults and Elderly

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

Influenza

United States
GlaxoSmithKline

Completed

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza | Influenza Vaccines

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults

Influenza A Subtype H7N7 Infection

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
GlaxoSmithKline

Completed

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Influenza | Influenza Vaccines

United States, Thailand, Canada
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
MedImmune LLC

Completed

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine (MI-MA205)

Healthy

United States
National Institute of Allergy and Infectious Diseases...

Completed

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

Influenza

United States
University of Rochester
National Institutes of Health (NIH)

Completed

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

2009 H1N1 Influenza Virus

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Influenza

United States
Novavax

Completed

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

Avian Influenza

Australia
Novartis Vaccines

Completed

Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years Old

Influenza

Dominican Republic
National Institute of Allergy and Infectious Diseases...

Completed

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Influenza | Influenza Immunisation | Avian Influenza

United States
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
Novartis Vaccines

Completed

Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects

Influenza

Japan
Sanofi

Completed

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Novavax
Department of Health and Human Services

Completed

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

Influenza (Pandemic)

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

HIV Infections | H1N1 Influenza Virus

United States, Puerto Rico
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
University of Rochester

Completed

Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine

Influenza

United States
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

Influenza A Virus, H7N9 Subtype

United States

3

Subscribe